Citi's Geoff Meacham: Novo misses on Alzheimer’s trial, but ‘winners keep winning’ in obesity drugs

Meanwhile, take a look at shares of Novo today falling to a four-year low this morning after results from its highly anticipated Alzheimer's drug trial failed to meet its main goal. The trial showed Novo's weight loss drug MGovi did not slow the progression of Alzheimer's. Joining us with some reaction today, city's head of US Pharma and biotech research Jeff Meum is with us.Jeff, thanks for the time. Good to see you again. >> Yeah, you too, Carl.Thank you for having me. >> I've seen the phrase longshot ass ...